Data exclusivity provided to biotech medicines does not prevent competition as long as generic-drug companies conduct their own safety and effectiveness research to launch their products, said Robert K. Coughlin, president of the Massachusetts Biotechnology Council, in response to a Boston Globe editorial. A health reform provision that would give 12 years of protection to brand-name biotech drugs would expand access to treatments and encourage innovation, and should not be compared to exclusivity given to traditional pharmaceuticals, Coughlin said.

Related Summaries